Cassava Sciences | PTIE - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 10.46B 1.15B 2026-06
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 2.98B 1.02B 2026-06
Cara Therapeutics USD 5.94M 983K 2025-09
Cassava Sciences USD 11.17M 2.38M 2026-03
Eisai JPY 215.74B 15.84B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Geron USD 52.07M 6.73M 2026-03
J&J USD 17.83B 388M 2026-06
Merck USD 18.17B 8.01B 2026-03
Novartis USD 10.2B 912M 2026-06
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Roche Holding CHF 18.9B 2.12B 2026-06